Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

Ganguli A, Wiegand P, Gao X, Carter JA, Botteman MF, Ray S.

Qual Life Res. 2013 Jun;22(5):1015-26. doi: 10.1007/s11136-012-0229-0. Epub 2012 Jul 18. Review.

PMID:
22806607
2.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
3.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.

Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Review.

5.

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 Nov;1(9):1042-58. Review.

6.

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW.

Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9.

7.

Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

Sanford M, Scott LJ.

Drugs. 2009 Nov 12;69(16):2303-28. doi: 10.2165/10489100-000000000-00000. Review.

PMID:
19852530
8.

An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.

Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB.

Ann Oncol. 2011 Aug;22(8):1805-11. doi: 10.1093/annonc/mdq682. Epub 2011 Jan 27.

PMID:
21273345
9.

[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].

Sun Y, Wu YL, Li LY, Liao ML, Jiang GL, Kim ES, Douillard JY, Milenkova T.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):377-80. Chinese.

PMID:
21875470
10.

[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].

Dai H, Xu L, Xia C, Chen W.

Zhongguo Fei Ai Za Zhi. 2013 Aug 20;16(8):405-10. doi: 10.3779/j.issn.1009-3419.2013.08.03. Chinese.

11.

Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.

Yang SC, Lai WW, Hsiue TR, Su WC, Lin CK, Hwang JS, Wang JD.

Qual Life Res. 2016 Jun;25(6):1441-9. doi: 10.1007/s11136-015-1174-5. Epub 2015 Nov 7.

PMID:
26545386
12.

Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 May;1(4):367-76. Review.

13.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
14.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY.

Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4.

PMID:
19027483
15.

A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.

Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A.

Appl Health Econ Health Policy. 2013 Feb;11(1):27-43. doi: 10.1007/s40258-012-0001-1. Review.

PMID:
23329379
16.
17.

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.

Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M.

Ann Oncol. 2009 Sep;20(9):1483-8. doi: 10.1093/annonc/mdp031. Epub 2009 Mar 12.

PMID:
19282468
18.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, Hirsch FR, Varella-Garcia M, Duffield E, Ataman OU, Zarenda M, Armour AA.

J Clin Oncol. 2009 May 1;27(13):2253-60. doi: 10.1200/JCO.2008.18.4408. Epub 2009 Mar 16.

19.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.

Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

PMID:
22277837
20.

Supplemental Content

Support Center